AbbVie declared a quarterly dividend on Thursday, February 16th. ET comments The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. My No. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. Build a CFD portfolio with your favourite companies. (844) 978-6257. The surge in revenues can primarily be attributed to its Allergan. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. Is this happening to you frequently? Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. ABBV Stock Forecast Price Target for 2024 TradingView View the best growth stocks for 2023 here. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. Payout ratios above 75% are not desirable because they may not be sustainable. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.79%. According to AbbVie CEO Rick Gonzalez, speaking on the Q2'22 earnings call, "Skyrizi's total prescription share of the U.S. biological market (in psoriasis) has increased to approximately 26%", and". What guidance has AbbVie issued on next quarter's earnings? Their ABBV share price forecasts range from $140.00 to $200.00. Johnson & Johnson Stock Forecast 2023 - 2025 - 2030 I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. Within the oncology division sales of Imbruvica fell 17% year-on-year. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. A Warner Bros. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. Your current $100 investment may be up to $188.28 in 2028. Skyrizi - which inhibits the activities of IL-23 - a naturally occurring cytokine that is involved in inflammatory and immune responses - and Rinvoq - a member of the janus kinase inhibitor drug class - fit this profile. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. The dividend payout ratio of AbbVie is 89.56%. In other words, no Humira, no problem! What is AbbVie's stock price forecast for 2023? Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. Read our dividend analysis for ABBV. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. American Consumer News, LLC dba MarketBeat 2010-2023. Only you can design whether Abbvie stock is the right investment for you. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. 1 dividend stock for a LIFETIME of income. AbbVie Inc. (ABBV) Analyst Ratings, Estimates & Forecasts - Yahoo Finance Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. Trial results demonstrated an overall response rate of 63% and a median duration of response of 12 months, where 39% of patients had already tried a CAR-T cell therapy. The Abbvie stock forecast for 2025 had the price at $259.018. The consensus among Wall Street research analysts is that investors should "hold" ABBV shares. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. $163.64. Management puts this down to "delayed market recovery for new patients starting therapy in Chronic Lymphocytic Leukemia ("CLL") and increasing competition" and has downgraded its FY22 guidance as a result. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. AbbVie made the bold decision to take on a heavy debt load and bid for Allergan, with the deal being completed in 2020. Please. Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. Richard A. Gonzalez has an approval rating of 88% among the company's employees. Investors are already flocking there for a chance at 1,000%+ returns. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. And it couldnt be more wrong! Since then, however, the stock price has fallen 18% to its current price of $142.6. AbbVie Stock: A Blue Chip You Cannot Afford To Miss, Yield 4.1% AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson . That reflects uncertainty about what the future holds for AbbVie. call (03) 8658 0539 support.au@capital.com. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. In 2022, the company will most likely boast 12 "blockbuster" (>$1bn per annum) selling assets, driving ~$48bn of revenues between them, with Humira being the only drug that faces a near term patent expiry, whilst AbbVie is promising at least 6 or 7 major new product launches by 2026. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Capital Com is an execution-only service provider. AbbVie has 5 focus areas for its research and products. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). You should do your own research and never invest money you cannot afford to lose. There are currently 9 hold ratings and 7 buy ratings for the stock. I have no business relationship with any company whose stock is mentioned in this article. I'm on twitter @edmundingham. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. AbbVie product revenue forecasts to 2030. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. AbbVie has a PEG Ratio of 3.51. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc.